Financial Performance - The company expects a net loss attributable to shareholders of between 20.5 million and 30.75 million RMB for the year 2024, compared to a profit of 63.55 million RMB in the same period last year [3]. - The projected net profit after deducting non-recurring gains and losses is expected to be a loss between 22 million and 32.5 million RMB, down from a profit of 55.32 million RMB in the previous year [3]. - Revenue is anticipated to be between 1,007 million and 1,180 million RMB, a decrease from 1,185.23 million RMB in the prior year [3]. Industry Challenges - The company cites intensified industry competition and the impact of healthcare payment reform as reasons for the decline in revenue and gross profit [5]. Cost Factors - Increased investments in innovative business, digitalization, and R&D projects have led to higher costs compared to the same period last year [5]. Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with final figures to be disclosed in the 2024 annual report [4][6].
何氏眼科(301103) - 2024 Q4 - 年度业绩预告